Phase2, single arm investigator initiated study of Atezolizumab in advanced or recurrent non-small cell lung cancer patients for biomarker research
Latest Information Update: 13 Aug 2020
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Aug 2020 Status changed from active, no longer recruiting to completed.
- 10 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2017 Status changed from not yet recruiting to recruiting.